🤝 PM $1.3M Delta-Hedged Put Cross — Paired With 80,000 Shares, Not a Bearish Bet

📅 July 1, 2026 | 🤝 Block Cross Detected

✅ Updated 2026-07-02: next-day OPRA OI confirms the OPEN — see the RESOLVED box.

---

🎯 The Quick Take

A desk just crossed 2,000 PM August $175 puts for ≈$1.3M — but the equity tape tells the real story: an 80,000-share PM stock block at $179.20 printed on the equity tape under Qualified-Contingent-Trade conditions just ≈1 second later. Run the delta math: the put's Black-Scholes delta is ≈0.38, implying a delta-neutral hedge of ≈75,600 shares — a 94.5% match to the 80,000-share block. This is NOT a bearish institution betting PM crashes; it is a delta-hedged protective structure executed right after yesterday's landmark FDA ZYN MRTP authorization, and 21 days before Q2 earnings on July 22.

---

📊 Company Overview

Philip Morris International (PM) is a global tobacco and nicotine company actively pivoting toward a smoke-free future:

• 💰 Market Cap: ≈$279B (≈1.56B shares outstanding)
• 📍 Exchange: NYSE — Consumer Staples, Tobacco
• 💲 Current Price: ≈$179.50 (July 1, 2026)
• 📊 52-Week Range: $142.11 (Nov 3, 2025 low) – $193.05 (Feb 2026 high)
• 🚬 Business: Combustible cigarettes (Marlboro outside the U.S.) + fast-growing smoke-free segment — IQOS heat-not-burn devices, ZYN oral nicotine pouches, and VEEV e-vapor. Smoke-free products now represent 43% of total net revenues as of Q1 2026
• 💵 Dividend Yield: ≈3.3% ($5.88/share annualized), with 17 consecutive years of increases

PM is one of the rare consumer staples names that combines a defensive income profile (high yield, pricing power on combustibles) with a genuine organic growth engine (smoke-free revenues growing +24.7% YoY as of Q1). That combination keeps institutional demand steady — and makes the structure of today's trade make sense.

---

💰 The Trade — Plain English

At 12:20 ET on July 1, 2026, a block of 2,000 PM August 21, 2026 $175 puts crossed at $6.49 each, for a total option premium of ≈$1.3M. The $175 strike sits ≈2.5% out-of-the-money with PM at ≈$179.50. Approximately one second later, a matched 80,000-share PM stock block at $179.20 printed on the equity tape under Qualified-Contingent-Trade (QCT) conditions — the exchange mechanism confirming a contingent, pre-arranged link between the options and stock orders.

This is a 🤝 BLOCK CROSS — a negotiated, pre-arranged transaction between two known counterparties, executed off the open displayed order book. It is not a lit-market aggressive sweep. There is no urgency signal here.

Trade Details

Paired equity leg (≈1 second later): 80,000 shares of PM @ $179.20 — Qualified-Contingent-Trade (QCT) on the equity tape

Delta math:

• Black-Scholes put delta at $179.50 spot, $175 strike, ≈51 DTE: ≈0.378
• Delta-neutral hedge implied by the option leg: 2,000 contracts × 100 shares × 0.378 = 75,600 shares
• Actual stock block: 80,000 shares
• Match: 80,000 / 75,600 = 94.5% delta match → the package is ≈delta-neutral at execution

---

✅ Open / Close — RESOLVED: July 2 Pre-Market OPRA OI Confirms an OPEN

The July 2 pre-market OPRA snapshot (reflecting July 1 EOD) is now in. Verdict: OPEN CONFIRMED. OI rose from ≈570 to 2,570 (+2,000) — exactly the print. Note this is part of a delta-hedged package, so a confirmed opening does not, by itself, imply a directional bearish bet.

OI rose by exactly ≈2,000 — a clean confirmed new opening long-put position (BTO), consistent with the delta-hedged structure described above.

---

🤓 What This Actually Means — Plain English

Let me break this down so it actually makes sense.

"Bought 2,000 puts" sounds bearish — until you read the stock tape.

When a big institutional desk executes a Qualified-Contingent-Cross (QCC), it submits an options order and a stock order as a pre-linked package. The exchange verifies the two legs are economically connected — the delta check — before printing both. The $175 put buy did NOT happen in isolation. It happened simultaneously with an 80,000-share long stock position at $179.20.

Here is the simplest translation: buy stock + buy a put on the same stock at the same time = a married put (or protective put structure). The put acts as insurance on the stock position. If PM falls below $175 before August 21, the put gains value dollar-for-dollar below that level, limiting the downside on the long stock. The desk executing this is NOT betting PM falls — they are protecting a long equity commitment against a defined downside scenario while keeping upside exposure.

Why right now? PM has a dense cluster of catalysts inside the option's 51-day life:

• FDA ZYN MRTP authorization (just yesterday, June 30) — a regulatory landmark that strengthens the long thesis
• $1.47/share dividend payment on July 20 (19 days away) — the long stock captures this
• Q2 earnings on July 22 — 21 days away; a binary event that could move the stock ±5-6%
• CFO transition on August 1 — telegraphed but still an execution watch item

Buying puts as a hedge before a binary earnings event, while holding long stock to collect a dividend, is textbook risk management — not a bearish conviction trade.

What is PROVEN from the tape:

• The QCC cross executed at 12:20:29 ET on the options side
• The paired 80,000-share QCT block at $179.20 ≈1 second later
• The 94.5% delta match between the option leg and the stock block
• Option size (2,000) exceeds prior OI (570) → opening transaction

What is INFERRED (strong — based on delta match and QCT conditions):

• This is a delta-neutral package — protective put structure or financing arrangement
• The desk is long PM equity with downside insurance, not net bearish

What the tape CANNOT tell us:

• The direction of the stock leg (buying vs. selling) — QCT conditions strongly imply a contingent hedge, but the equity tape's exact sign is not visible from the options tape
• Whether the stock leg is a new purchase or protection overlaid on a pre-existing position
• The desk's identity, prime broker, or any prior holdings
• Whether the puts will be held to expiry or monetized/unwound before August 21

Do NOT interpret the "$1.3M put buy" headline in isolation as a directional bearish signal on PM.

---

📈 Technical Setup / Chart Check-Up

YTD Performance

Philip Morris has been on a complex journey in 2026. After surging from its November 2025 low of $142.11 to a February 2026 high near $193.05, the stock has since pulled back and consolidated near ≈$179.50 — sitting about 6-7% below those highs as the market balanced U.S. ZYN inventory normalization (Q1 volumes −23.5%) against powerful international smoke-free momentum (smoke-free revenues +24.7%, IQOS volumes +11.3%).

The stock has been ranging roughly $179–$186 in recent sessions — tight consolidation ahead of two catalysts stacked in quick succession: the $1.47/share dividend on July 20 and Q2 earnings pre-market on July 22.

Key chart observations:

• 📈 Strong recovery: From the $142 low to current $179 = +26% recovery, reflecting the smoke-free growth re-rating and analyst upgrades
• 🎢 Consolidation phase: ≈6-7% below February highs as U.S. destock and FX weigh; the market is waiting for evidence of ZYN Ultra uptake and Q2 U.S. recovery
• 💵 Dividend support: The $1.47/share payout on July 20 provides near-term fundamental support — institutional longs won't typically exit in size just before a dividend
• 📊 Analyst consensus at ≈$210 (BofA $209, Morgan Stanley $200) suggests significant long-term upside from current levels, even if near-term is catalyst-dependent

Gamma-Based Support & Resistance Analysis

Current Price: ≈$179.50

The gamma exposure map shows PM sitting in a tightly bracketed zone, with meaningful levels both just above and below current price:

🟠 Resistance Levels (Call Gamma Above Price):

• $180 — Moderate gamma resistance (total GEX ≈3.4B), just 0.19% above current price. PM is essentially sitting right up against this ceiling. Call gamma is dominant here (call GEX ≈2.55B vs put GEX ≈0.82B), meaning market makers are net short calls at $180 and will sell into any test of that level
• $185 — Next resistance (total GEX ≈3.2B, net GEX +1.90B call-dominant), ≈3.0% above current. A secondary ceiling with similar strength to $180
• $190 — Extended call wall (total GEX ≈1.5B), ≈5.8% above — would require a meaningful post-earnings breakout to reach

🔵 Support Levels (Put Gamma Below Price):

• $175 — Significant put-heavy gamma cluster (total GEX ≈2.0B, net GEX −0.41B meaning put gamma dominates). This is exactly the strike of today's block-cross trade, sitting ≈2.6% below current price. Heavy put open interest at this level means market makers carry delta hedges that support the stock near $175 — it tends to act as a gravitational floor
• $170 — Next put support layer (total GEX ≈1.2B, net GEX −0.41B), ≈5.4% below
• $165 — Deeper put support (total GEX ≈1.2B, net GEX −0.98B — the heaviest put-to-call skew in the chain), ≈8.2% below

What this means for traders: PM is sandwiched between the $175 put wall and the $180 call ceiling — a natural ≈$5 range. Market makers with gamma at both levels will tend to contain price movement within that band, especially heading into the dividend (July 20) and earnings (July 22). Breakout above $180 with conviction opens a path toward $185; a decisive breakdown below $175 removes that gamma support and accelerates toward $170.

The fact that today's trade struck precisely at the $175 put wall is not coincidental — that level already had meaningful open interest, and adding 2,000 more contracts reinforces it as a key structural floor through August 21.

Implied Move Analysis

The options market is pricing the following expected moves for PM from current ≈$179.50:

For this specific trade (August 21 expiry): the market is pricing PM anywhere from ≈$159.84 to ≈$199.48 by expiration — a wide range that fully encompasses the $175 put strike within the lower half. At spot ≈$179.50 vs. strike $175, the put is ≈2.5% OTM today. The implied move lower bound by August 21 is ≈$159.84, which is well below $175 — the market assigns a meaningful probability that PM reaches, or falls through, $175 before expiry.

The earnings window is key: Q2 results land July 22, a full 30 days before this option expires. If earnings disappoint (U.S. ZYN recovery slower than expected; impairment headline noise), PM could test the $169-175 gamma support zone — exactly where this put's protection would be most valuable to a long stock holder.

Translation for regular folks: Options traders are pricing a ±1.77% move by tomorrow (July 2), but a ±5.9% move through the July 17 monthly OPEX, which captures the earnings catalyst on July 22. By August 21, the range expands to nearly ±$20 in either direction. The $175 put is designed to profit if PM falls into the lower portion of that range.

---

🎪 Catalysts

🔥 Immediate Catalysts (Now Through August 21)

FDA ZYN MRTP Authorization — June 30, 2026 (just happened)

Yesterday, the FDA issued Modified Risk Tobacco Product orders for 20 ZYN nicotine pouch products — the first-ever reduced-risk marketing authorization for any nicotine pouch, per CNBC's coverage of the FDA ruling. ZYN can now legally state in marketing that switching from cigarettes to ZYN reduces risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis. Rivals (BAT's Velo, Altria's on!) lack this authorization — a meaningful competitive moat. The 20 ZYN SKUs already had FDA sale authorization (January 2025); this MRTP order adds the health-claim marketing right, a durable regulatory differentiator.

ZYN Ultra U.S. Launch — June 2026

New 9mg and 11mg moist ZYN Ultra variants launched in June 2026, expanding the U.S. ZYN portfolio at higher strength levels. This is aimed at re-accelerating U.S. pouch volumes after the painful Q1 destock (ZYN shipments −23.5% in Q1). The Q2 earnings call (July 22) will provide the first meaningful sell-in data on ZYN Ultra — a critical read for the U.S. recovery thesis.

Q3 Quarterly Dividend — $1.47/share, July 20, 2026

PM's $1.47/share quarterly dividend is payable July 20, with a record date of June 25. The annualized dividend is $5.88 per share (≈3.3% yield). PM has raised its dividend for 17 consecutive years — a commitment that keeps long-term institutional holders steady. The long stock side of today's hedged package benefits directly from this payout in 19 days.

Q2 2026 Earnings — July 22, 2026 (pre-market)

This is the binary event the put is most clearly hedging against. Per Nasdaq/Zacks consensus:

• Consensus adjusted EPS: ≈$2.03 (vs. $1.91 year-ago; company guide $1.97–$2.02 post-FX revision)
• Consensus revenue: ≈$10.25B (+8.3% YoY)
• Smoke-free net revenue: ≈$4.23B (+19.7% YoY)

Key watch items for July 22: U.S. ZYN volume recovery trajectory + ZYN Ultra initial sell-in; IQOS international volumes; the ≈$500M RBH non-cash impairment landing in reported (not adjusted) EPS; and any FY guidance refresh. PM has beaten EPS estimates in each of the last four quarters, per Barchart, but the impairment and FX noise may cloud the headline.

CFO Transition — August 1, 2026

Massimo Andolina takes over as Group CFO on August 1, 2026, succeeding Emmanuel Babeau (who stays as Strategic Advisor through March 2027). The transition is orderly and telegraphed — announced May 20, Andolina is a PMI insider since 2008 — but it is still an execution watch item during a pivotal smoke-free scaling phase. This event falls inside the August 21 option expiry window.

📋 Recent Catalysts (Context)

Q1 2026 Earnings (April 22): PM beat consensus — adjusted EPS $1.96 vs. $1.83 expected; net revenues +9.1% to ≈$10.1B; smoke-free revenues +24.7%; raised FY2026 adjusted EPS guidance to $8.36–$8.51. U.S. revenues −30.8%; ZYN shipments −23.5% as inventory normalized — a drag the market has been watching carefully.

Guidance revision (June 1): PM updated FY2026 diluted EPS for currency and the ≈$500M RBH non-cash impairment only. Reported EPS trimmed to $7.18–$7.33; adjusted EPS narrowed to $8.31–$8.46. Yahoo Finance noted shares eased modestly on the impairment headlines despite the adjusted EPS being largely intact.

Analyst upgrades (June 2026): BofA raised its PM price target to $209 (Buy); Morgan Stanley raised to $200 (Overweight). Consensus Buy rating with blended price target of ≈$210, citing smoke-free expansion, ZYN Ultra upside, and an orderly CFO handoff.

---

🎲 Price Targets & Scenario Analysis

Using the gamma exposure map and implied move data as of July 1, and incorporating the catalyst stack:

📈 Bull Case — Smoke-Free Execution Delivers, ZYN Ultra Inflects (30% probability)

Target by August 21: $185–$193

• Q2 earnings beat: U.S. ZYN recovery begins (even modest vs. Q1's −23.5% base impresses), ZYN Ultra strong initial sell-in, IQOS international volumes +10%+
• FDA MRTP halo effect measurably lifts ZYN marketing efficiency and mindshare vs. rivals
• Stock breaks above $180 gamma resistance → clears path to $185 (next moderate call wall) → approaches prior February high of ≈$193
• Implied move upper by August 21: ≈$199 — within reach in a strong bull run, supported by analyst consensus near $210
• In this scenario: the put protection expires near-worthless, the desk's long stock position captures the gain

🎯 Base Case — In-Line Earnings, Consolidation Continues (50% probability)

Target: $175–$183

• Q2 results in-line to slight beat on adjusted EPS ($2.00-$2.03); U.S. ZYN recovery "early but real"; impairment headline creates optics noise but is non-cash
• Stock gravitates in the $179-180 gamma pin zone; $180 call resistance and $175 put support contain the range pre-/post-earnings
• Dividend on July 20 ($1.47/share) provides near-term floor support
• Put expires with minimal intrinsic value or out-of-the-money; served as insurance that was not needed
• Longer-term bull case toward analyst targets of $200+ remains intact but plays out over 6-12 months, not in 51 days

📉 Bear Case — U.S. ZYN Misses, Impairment Headlines Dominate (20% probability)

Target: $165–$175

• Q2 miss: U.S. ZYN volumes still negative and ZYN Ultra sell-in slower than expected; management lowers U.S. growth trajectory
• ≈$500M RBH impairment drives negative headlines even though adjusted EPS holds
• FX impact worse than expected ($0.03+ per share drag)
• Stock breaks below $175 gamma put wall → accelerates toward $170 (next put support), potentially $165 (heaviest put gamma in the chain, ≈8% below)
• This is exactly when the protective put activates: below $175, the PM August $175 put gains ≈$1 for every $1 PM falls, offsetting losses on the 80,000-share stock position

The put breakeven (option leg in isolation): $175 strike − $6.49 premium = $168.51. Below that level, the put is generating net profit on the option. In the delta-hedged context, the "profit" on the put is offsetting losses on the long stock — this is exactly how a protective put (married put) functions, not a speculative directional trade.

---

💡 Trading Ideas for Retail Traders

These are NOT copies of the block cross trade. They are retail-sized approaches given the current PM setup, gamma levels, and upcoming catalysts. Size all positions appropriately for your risk tolerance — options can and do expire worthless.

🛡️ Conservative: Cash-Secured Put Below $175 Gamma Support

The Play: Sell the August 21, 2026 $175 put (same expiry as today's trade) and collect ≈$6.49/share in premium while you are willing to own PM at the $175 level.

Why this works:

• You collect ≈$649 per contract in premium up front
• The $175 put wall is reinforced by today's new block (now 2,000+ more contracts of open interest at this level)
• If PM stays above $175 through August 21, the put expires worthless and you keep the full premium
• If assigned, your effective cost basis is $175 − $6.49 = $168.51 — near the implied move lower bound by expiry and well below analyst price targets of $200+

Risk: PM falls sharply below $175 post-earnings and continues lower — you are assigned at $175 with an unrealized loss developing. Define position size so assignment does not strain your account.

Skill level: Intermediate (requires options selling approval)

⚖️ Balanced: Bull Put Spread Below the $175 Put Wall

The Play: Sell the August 21 $175 put, Buy the August 21 $165 put — a $10-wide defined-risk bull put spread.

Why this works:

• Collects ≈$3-4 net credit depending on exact fills
• Maximum loss is limited to ≈$6-7 per spread (defined), even if PM collapses
• Breakeven near ≈$171-172 — below both the gamma support at $175 and the current implied move lower bound at ≈$160
• The spread profits if PM holds above $175 through August 21, which gamma structure and the bullish analyst consensus ($200+) support as the base case
• The $165 long put provides protection if the bear case materializes unexpectedly

Skill level: Intermediate

🚀 Aggressive: Bull Call Spread Into Earnings Catalyst

The Play: Buy the August 21 $180 call, Sell the August 21 $190 call — a $10-wide bull call spread.

Why this could work:

• Targets PM recapturing ground toward analyst consensus ($200+ targets)
• The July 22 earnings catalyst is the trigger: a solid Q2 beat with ZYN Ultra traction + FDA MRTP halo could break $180 call resistance and run toward $185-190
• Cost ≈$3-4 debit; max payout ≈$6-7 if PM closes above $190 at August 21 expiry

Why it could blow up:

• PM disappoints on U.S. ZYN recovery, stock stays pinned below $180, spread expires worthless
• Implied volatility crush post-earnings could reduce option premiums even if PM moves modestly up
• The $180 gamma ceiling creates real mechanical selling pressure from market makers

Never risk more on this play than you are prepared to lose entirely — earnings create binary outcomes.

Skill level: Intermediate to Advanced

---

🎭 4-Reader Interpretation

1. 🎰 YOLO Trader

Do NOT chase puts here because "a whale bought puts." The 2,000-contract put buy was packaged with 80,000 shares of long stock — it is literally a hedge on a long position, not a directional short. Buying PM puts because this tape printed would be reading the headline and missing the story. If you want to express a PM view into earnings, options are available on both sides — but size small, because the implied move of ±5.89% through July 17 OPEX tells you the market expects a real move either way. Choose your direction based on your fundamental read of the ZYN recovery, not on this cross.

2. 📈 Swing Trader

This is a rich setup for the next 3 weeks. The gamma map puts PM in a clear $175-$180 range with hard levels on both sides. The playbook:

• Watch for a confirmed break above $180 on strong Q2 earnings (July 22) → swing long toward $185-190, with the implied move upper by Aug 21 at ≈$199 as an extended target
• Watch for a breakdown below $175 on earnings miss → momentum could flush toward $170-165; reassess at $170 gamma support
• July 20 dividend ($1.47/share) is a near-term reason to be long heading into earnings

The block cross tells you an institutional desk is long PM stock with downside insurance — a bullish-leaning stance, managed prudently. Follow the positioning, not the put option in isolation.

3. 💰 Premium Collector

PM is a classic staples name with lower implied volatility than growth tech — but the near-term catalyst stack (earnings July 22, ZYN Ultra data, CFO change, MRTP reaction) provides enough premium to make put spreads attractive. The $175 put wall has meaningful structural support — sell put spreads below it ($175/$165 August 21 bull put spread is the cleanest structure given today's tape). The August 21 or September 18 expirations capture post-earnings theta decay. Maintain strict position sizing — staples names can gap on earnings misses more than their low-IV reputation implies.

4. 🌱 Entry-Level Investor (Just Getting Started with Options and Flow)

Here is the single most important lesson from today's tape: a "big put buy" is not always bearish. When you also see a huge stock purchase on the equity tape at the same moment — which you need to check for every single large cross — the put is acting as insurance on the stock position, not a bet that the stock crashes.

Think of it this way: buying a house (the 80,000 shares) and simultaneously purchasing homeowner's insurance (the 2,000 puts) in the same transaction. The insurance is protection, not a belief the house burns down.

If you are learning about PM as a company: it is a high-quality dividend grower (3.3% yield, 17 straight years of increases) with a real growth engine in smoke-free products. Yesterday's FDA ZYN authorization was a landmark win. Q2 earnings on July 22 are the next big test. If you are new to options flow, start by understanding what a protective put does before interpreting large institutional prints — context is everything.

---

⚠️ Honest Risk Factors

What the tape CANNOT prove:

• The exact direction of the 80,000-share stock leg — QCT conditions strongly suggest a contingent long-side hedge, but the equity tape's sign requires independent verification
• Whether the stock block represents a new position or protection being layered on pre-existing shares
• The desk's identity, prime broker, full portfolio context, or whether they will unwind before August 21
• That any portion of this trade represents information the desk has that we do not

Fundamental risks for PM:

• 🇺🇸 U.S. ZYN recovery risk: Q1 ZYN shipments were −23.5% — a second consecutive quarter of U.S. softness would put the near-term growth narrative at risk and could push shares through the $175 gamma floor toward $170
• 📰 Impairment headline noise: The ≈$500M RBH non-cash charge will cut reported Q2 EPS by ≈$0.33; headline-driven algorithms may react negatively even though adjusted EPS ($1.97–$2.02 guided) is largely intact. Know the difference between reported and adjusted EPS before trading earnings
• 💱 FX headwind: PM is internationally weighted and earns revenues in dozens of currencies. A strong dollar is a persistent translation drag — management guided ≈$0.03 unfavorable FX impact on Q2 EPS alone
• 🏭 ZYN Ultra sell-in timing: Launching a new product immediately before earnings creates asymmetric risk — a strong early sell-in is a positive catalyst, but a slow consumer pull-through would disappoint the U.S. recovery thesis
• 🩺 Regulatory wildcard: The FDA MRTP is a win, but public-health advocacy organizations have signaled pushback on flavored pouch marketing and social-media promotion. Future flavor or menthol restrictions globally remain an unpriceable tail risk
• 📋 CFO transition (August 1, within the option window): Andolina's appointment is orderly, but any unexpected shift in capital allocation guidance (buybacks, dividend policy, smoke-free investment pace) under new leadership could move the stock around the August 1 date
• 📊 Valuation at a premium: At ≈$279B market cap and a ≈21-22× forward adjusted EPS multiple (on $8.31–$8.46 guidance), PM carries a premium vs. traditional tobacco peers. Any material deceleration in smoke-free growth would compress that multiple

---

🎯 The Bottom Line

Real talk: A desk just executed a textbook risk-management trade. They built a meaningful long PM stock position — right after the most important tobacco regulatory win in years (the FDA's June 30 ZYN MRTP authorization) — and simultaneously bought put insurance before the Q2 earnings binary event and a CFO transition. The put is the seatbelt on the car, not a bet the car crashes.

The signal embedded in this block cross is actually subtly bullish on PM's long-term story: a sophisticated institutional desk chose to be long 80,000 shares at $179.20, the day after the FDA landmark, 21 days before earnings, and 19 days before collecting a $1.47/share dividend. They just hedged the short-term binary risk with puts — standard portfolio management for a position of this size.

If you are watching PM:

• ✅ $175 = your key support level — reinforced by the new open interest from today's block and existing gamma
• 🟠 $180 = your immediate ceiling — breaking and holding above $180 is the first bull signal; watch for volume confirmation
• 📅 Mark July 20 (dividend, $1.47/share) and July 22 (Q2 earnings pre-market, THE catalyst) on your calendar now
• 📈 A Q2 beat with early ZYN Ultra traction could push shares back toward $185-190 and materially toward the analyst consensus of ≈$210 over the next 6-12 months
• 🛡️ Defined-risk structures (bull put spreads below $175) offer income with contained downside in the base case
• ⚠️ Avoid naked short puts or calls without fully understanding the maximum loss — earnings create gap risk

Key dates to watch:

• ✅ July 2 — OPRA OI confirmed the OPEN (resolved): PM August 21 $175 put OI rose from ≈570 to 2,570 (+2,000), confirming today's opening position
• 📅 July 20 — Q3 quarterly dividend payment ($1.47/share)
• 📅 July 22 (before market open) — Q2 2026 earnings report — THE catalyst for the August 21 option window
• 📅 August 1 — CFO Massimo Andolina takes the seat
• 📅 August 21 — Monthly OPEX, expiration of today's block-cross position

PM's long-term smoke-free story — IQOS growing at +11% volumes, ZYN with a now-unique FDA health-claim authorization, and a disciplined 17-year dividend growth track record — remains intact. One sophisticated desk has just said, with its capital: this story is worth owning at $179.20, with a seatbelt on through earnings. That is a fundamentally bullish message wrapped in prudent risk management.

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. This analysis is for educational and informational purposes only and does not constitute financial or investment advice. The block cross structure described here involves complex options and equity mechanics not suitable for retail investors to replicate directly. Past institutional activity does not guarantee future returns. All price targets and scenario probabilities are illustrative estimates based on publicly available data; actual results may differ materially. Always conduct your own research and consider consulting a licensed financial advisor before trading. Options can expire worthless, resulting in total loss of premium paid.

---

Analysis published July 1, 2026 | Philip Morris International (PM)

Last updated: 2026-07-02 — open/close resolved via next-day OPRA OI (reflecting July 1 EOD).